Other headlines:PETNET extends supply of radioisotopeFonar customer logs fifth UpRight
Dr. Paul E. Berger has cut all formal ties with NightHawk Radiology, a company he helped found eight years ago. Berger stepped down June 8 as nonexecutive chairman of the board, a position he has held since Nov. 15, when he resigned as CEO of the company. In connection with his resignation this week from the board, Berger informed NightHawk that he could no longer support the direction, policies, business strategies, and initiatives that the company has adopted, according to a NightHawk filing with the Securities and Exchange Commission.
Siemens subsidiary PETNET Solutions will supply an experimental PET radioisotope for the phase II and III trials examining its value as a cardiac perfusion agent. The radiotracer, BMS747158, is a novel fluorine-18-labeled tracer developed by Lantheus Medical Imaging for myocardial perfusion imaging in subjects under rest and stress conditions. Lantheus is running the trials. PETNET Solutions operates a network of 52 radiopharmacies and distribution centers worldwide that manufacture and distribute PET biomarkers.
If repeat business is the most sincere compliment, few companies get more praise than Fonar, at least from Tampa-based Rose Radiology. The 10-center radiology chain on Florida's west coast has bought its fifth UpRight MR scanner from Fonar. Rose was among the first to begin uing an UpRight MR. This scanner, which began operating about seven years ago, was the first installed in Florida and the second in the world, according to Fonar.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.